Core Insights - The Big Beautiful Bill Act (BBBA) is projected to cut $1 trillion from Medicaid, which constitutes 62% of Centene's 2024 revenue [2][4] - Centene's stock experienced a 40% decline following the withdrawal of its 2025 revenue guidance due to an independent actuary's report indicating overly optimistic revenue assumptions [2][3] - S&P Global Ratings is contemplating downgrading Centene's credit rating to junk status, which could increase the company's cost of capital [4][14] Financial Performance - Centene's revenue from Medicaid was $101.4 billion, representing 62% of total revenue for 2024, while Medicare contributed 14% and the Commercial Marketplace business unit accounted for 21% [7] - In Q1 2025, Centene reported a 15.4% increase in revenue to $46.6 billion, exceeding analyst expectations [16] - The company’s adjusted earnings per share (EPS) for Q1 2025 was $2.90, which was 22.9% higher than consensus estimates [16] Market Impact - The BBBA's Medicaid cuts could reduce Centene's revenue growth rate by one percentage point annually over the next five years, from 5% to 4% [13] - Analysts have expressed concerns about the potential for Centene's EPS forecast to be significantly lowered, with estimates suggesting a possible reduction of $2.75 [11][12] - Despite the negative outlook, some analysts believe Centene is significantly undervalued, with a 12-month price target averaging $63.08, indicating a potential upside of nearly 91% [20] Strategic Concerns - The withdrawal of revenue guidance has raised questions about Centene's future profitability and capital adequacy, leading to increased scrutiny from credit rating agencies [15] - The company faces challenges in offsetting potential revenue losses from Medicaid cuts with other business lines [8] - The healthcare sector, particularly managed care, is viewed as increasingly risky by some analysts, with concerns that conditions may worsen before improving [19]

Company Overview - Community Healthcare Trust Incorporated is a real estate investment trust focusing on owning income-producing real estate properties primarily associated with outpatient healthcare services across the United States [3] - As of March 31, 2025, the company had approximately $1.2 billion in investments across 201 real estate properties, totaling around 4.5 million square feet, located in 36 states [3] Upcoming Events - The company will report its second-quarter results for 2025 on July 29, 2025, after market close [1] - A conference call to discuss the earnings results, quarterly activities, and industry trends will be held on July 30, 2025, at 9:00 a.m. Central Time, with a simultaneous webcast available [2]

Key Takeaways Chewy added 240K customers in Q1, growing active customers 3.8% y/y to 20.8M. Higher reorder rates, lower churn and stronger customer spend improved retention quality. Net sales grew 8.3% to $3.12B, fueled by Autoship, pharmacy, vet clinics and Chewy expansion.Chewy (CHWY) demonstrated a noticeable acceleration in active customer growth in the first quarter of fiscal 2025, reflecting the success of its ongoing customer acquisition and retention strategies. The company closed the quarter with ...

Company Overview - Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease through intuitive, intelligent, and connected monitoring and therapeutic intervention technologies [3] Financial Results Announcement - Kestra Medical Technologies will report its fourth quarter and fiscal year 2025 financial results on July 15, 2025 [1] - A conference call will be hosted by management at 4:30 p.m. Eastern Time on the same day [1] Conference Call Details - A live and archived webcast of the conference call will be available in the "Events" section of the investor relations website [2] - Participants are encouraged to register on the website at least 10 minutes prior to the start of the conference call [2]

Core Insights - Virtual healthcare services, or telehealth, are becoming a standard in the digital healthcare space, with companies like Hims & Hers Health, Inc. (HIMS) and LifeMD, Inc. (LFMD) emerging as key players providing direct-to-consumer services [1][2] Company Overview - Hims & Hers is focused on transforming health and wellness needs for consumers, while LifeMD offers cost-effective telehealth solutions for comprehensive virtual and in-home healthcare [2] - HIMS is expanding into Europe through the acquisition of ZAVA, targeting markets such as Germany and France, while LFMD's Wegovy program has enrolled over 75,000 patients, indicating strong market traction [6][8][10] Stock Performance & Valuation - Over the past three months, HIMS has increased by 67.2%, while LFMD has risen by 152.8%. However, in the past year, HIMS has gained 130.7% compared to LFMD's 102.2% [3] - HIMS has a forward price-to-sales (P/S) ratio of 4.3, above its three-year median of 2.3, while LFMD's ratio is 2.2, also above its median of 0.9 [5] Earnings Projections - HIMS expects a 170.4% growth in EPS for 2025, compared to LFMD's projected 107.6% growth [6][15][17] - The Zacks Consensus Estimate for HIMS' 2025 EPS suggests a significant improvement from 2024, while LFMD's estimate also indicates growth [15][17] Strategic Initiatives - HIMS is focusing on expanding into new specialty areas that can be treated via telehealth, such as sleep disorders and hypertension, which align with its business model [7] - LifeMD's Wegovy program integrates medication with virtual care, providing a compliant solution for weight loss therapy, which is in high demand [10][11] Financial Health - LifeMD reported first-quarter revenues of $65.7 million and net income of $1.4 million, showing a turnaround from previous losses, supported by $34.4 million in cash [12] - HIMS is utilizing proceeds from its $870 million convertible senior notes offering to support global expansion and investment in AI and personalized treatments [9] Investment Outlook - HIMS is viewed as a more stable investment opportunity with strong profitability and user engagement, while LFMD is recognized for its rapid growth and expansion [24][25] - Analysts have set average price targets for HIMS at $46.17 and for LFMD at $12.81, both indicating potential declines from their last close [20][22]

The Medical Services sector is experiencing significant transformation fueled by advancements in technology, increased adoption of value-based care and focus on patient-centric solutions and precision medicine. Rising demand for remote treatment is accelerating digital healthcare growth, especially in telemedicine and AI-powered analytics. Providers are using these tools to improve diagnostics, streamline operations, and enhance outcomes, while value-based models promote preventive and personalized care.Acc ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? Developed alongsid ...

Core Viewpoint - Waterdrop (NYSE: WDH) has largely recovered from the stock market turmoil that led to a sell-off in March and April, indicating resilience in its business model and market position [1]. Company Summary - Waterdrop operates a platform that provides insurance and healthcare services in China, positioning itself in a growing market with significant potential for expansion [1]. Market Context - The stock market volatility experienced in early 2023 had a notable impact on Waterdrop's stock performance, but the company has shown signs of recovery since then [1].

Institucionalização das contas de saúde no Brasil Uma revisão sobre métodos, dados e relevância para as políticas públicas Institucionalização das contas de Institucionalização das contas de saúde no Brasil UMA REVISÃO SOBRE MÉTODOS, DADOS E RELEVÂNCIA PARA AS POLÍTICAS PÚBLICAS Este estudo foi publicado sob a responsabilidade do Secretário-Geral da OCDE. As opiniões expressas e os argumentos utilizados nesta publicação não refletem necessariamente a posição da Organização nem dos Governos de seus países me ...

Core Viewpoint - Aveanna Healthcare Holdings Inc. has completed the acquisition of Thrive Skilled Pediatric Care, enhancing its position in the pediatric home care market and expanding its service offerings into new states [1][2][3]. Company Overview - Aveanna Healthcare is a diversified home care platform providing services to medically complex, high-cost patient populations, with a presence in 36 states [7]. - The company offers a wide range of healthcare services, including nursing, rehabilitation, therapy, and case management, aimed at providing high-quality, lower-cost alternatives to prolonged hospitalization [7]. Acquisition Details - Thrive SPC is one of the largest independent providers of pediatric home care, operating 23 locations across seven states [2]. - The acquisition is expected to create significant growth opportunities for Aveanna, reinforcing its commitment to clinical excellence and compassionate care [3]. - The deal was financed through a combination of common stock and cash [3]. Strategic Implications - The integration of Thrive SPC is anticipated to enhance Aveanna's existing footprint and introduce its specialized care model into two new states [2][3]. - The acquisition aligns with Aveanna's strategic mission to lead in delivering high-quality care while providing value and clinical innovation to payors and stakeholders [3]. Advisory and Legal Support - Edge Healthcare Partners acted as the financial advisor for Aveanna, while Cantor Fitzgerald & Co. served as the financial advisor for Thrive SPC [4]. - Legal counsel for Aveanna was provided by Bass, Berry & Sims, and Ropes & Gray LLP represented Thrive SPC [4].